Literature DB >> 22817861

Diabetic revascularization: endovascular versus open bypass--do we have the answer?

Michael S Conte1.   

Abstract

Diabetes is an independent risk factor for peripheral arterial disease and, when advanced peripheral arterial disease develops in the setting of diabetes, it portends a greatly increased threat to both life and limb. The management of severe limb ischemia in diabetic patients, particularly those with tissue loss and infection, remains a major surgical challenge in the new millennium. However, advances in multidisciplinary care, including an aggressive revascularization approach, can avoid major amputation in a large percentage of patients. The unique pattern of lower extremity atherosclerosis in diabetes is a critical determinant of the revascularization strategy. Most diabetics with critical ischemia have popliteal/tibial occlusions requiring below-the-knee intervention or bypass grafting. Bypass surgery with vein to crural or pedal arteries remains the gold standard of revascularization, but may be limited by patient risk, conduit availability, and a suitable target. Infrapopliteal angioplasty can have acceptable results for suitable lesions, particularly when there is not extensive tissue loss in the foot. However, restenosis rates after endovascular intervention in these vessels are high, and recent advances in drug-eluting balloons and stents have promise but remain largely unproven. There is limited high-quality evidence to support treatment choices in this arena, with only one randomized clinical trial to date. The available data suggest that patients with life expectancy of at least 2 years and more extensive disease have superior outcomes with open reconstruction. A selective revascularization strategy is advocated, using autogenous vein bypass as the initial approach in a significant percentage of patients, based on its greater overall efficacy and proven durability. However, endovascular therapies have an important role in current practice, which will increase further if restenosis can be overcome. Vascular specialists should understand and be able to apply both types of interventions to optimize patient outcomes.
Copyright © 2012. Published by Elsevier Inc.

Entities:  

Mesh:

Year:  2012        PMID: 22817861     DOI: 10.1053/j.semvascsurg.2012.04.004

Source DB:  PubMed          Journal:  Semin Vasc Surg        ISSN: 0895-7967            Impact factor:   1.000


  13 in total

1.  Burden of Infected Diabetic Foot Ulcers on Hospital Admissions and Costs.

Authors:  Caitlin W Hicks; Shalini Selvarajah; Nestoras Mathioudakis; Ronald E Sherman; Kathryn F Hines; James H Black; Christopher J Abularrage
Journal:  Ann Vasc Surg       Date:  2016-02-22       Impact factor: 1.466

2.  Angiosome-targeted revascularisation in diabetic foot ulcers.

Authors:  Raffaele Serra; Raffaele Grande; Edoardo Scarcello; Gianluca Buffone; Stefano de Franciscis
Journal:  Int Wound J       Date:  2013-10-07       Impact factor: 3.315

3.  Fifteen-year trends in lower limb amputation, revascularization, and preventive measures among medicare patients.

Authors:  Philip P Goodney; Massimo Tarulli; Adrienne E Faerber; Andreas Schanzer; Robert M Zwolak
Journal:  JAMA Surg       Date:  2015-01       Impact factor: 14.766

4.  Cardiovascular and Limb Events Following Endovascular Revascularization Among Patients ≥65 Years Old: An American College of Cardiology PVI Registry Analysis.

Authors:  E Hope Weissler; Yongfei Wang; Jordan M Gales; Dmitriy N Feldman; Shipra Arya; Eric A Secemsky; Herbert D Aronow; Beau M Hawkins; J Antonio Gutierrez; Manesh R Patel; Jeptha P Curtis; W Schuyler Jones; Rajesh V Swaminathan
Journal:  J Am Heart Assoc       Date:  2022-06-20       Impact factor: 6.106

5.  Bypass versus endovascular intervention for healing ischemic foot wounds secondary to tibial arterial disease.

Authors:  Abhisekh Mohapatra; Jon C Henry; Efthimios D Avgerinos; Aureline Boitet; Rabih A Chaer; Michel S Makaroun; Steven A Leers; Eric S Hager
Journal:  J Vasc Surg       Date:  2018-01-11       Impact factor: 4.268

6.  New thoughts in an old player: role of nitrite in the treatment of ischemic revascularization.

Authors:  Guanghong Jia; James R Sowers
Journal:  Diabetes       Date:  2014-01       Impact factor: 9.461

7.  Long-term outcomes of infrainguinal bypass surgery for patients with diabetes mellitus and tissue loss.

Authors:  Heekyung Jung; Jayun Cho; Hyung-Kee Kim; Jihye Kim; Seung Huh
Journal:  Ann Surg Treat Res       Date:  2014-12-26       Impact factor: 1.859

8.  Role of comorbidities as limiting factors to the effect of hyperbaric oxygen in diabetic foot patients: a retrospective analysis.

Authors:  Esra A Akgül; Jale Karakaya; Salih Aydın
Journal:  Diabetes Ther       Date:  2014-10-02       Impact factor: 2.945

9.  Diabetic foot: surgical approach in emergency.

Authors:  C Setacci; P Sirignano; G Mazzitelli; F Setacci; G Messina; G Galzerano; G de Donato
Journal:  Int J Vasc Med       Date:  2013-10-23

10.  IN.PACT Amphirion paclitaxel eluting balloon versus standard percutaneous transluminal angioplasty for infrapopliteal revascularization of critical limb ischemia: rationale and protocol for an ongoing randomized controlled trial.

Authors:  Thomas Zeller; Iris Baumgartner; Dierk Scheinert; Marianne Brodmann; Marc Bosiers; Antonio Micari; Patrick Peeters; Frank Vermassen; Mario Landini
Journal:  Trials       Date:  2014-02-19       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.